Nasus Pharma Ltd. (NSRX)
| Market Cap | 63.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.53M |
| Shares Out | 9.06M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,101 |
| Open | 6.50 |
| Previous Close | 6.75 |
| Day's Range | 6.50 - 7.00 |
| 52-Week Range | 5.90 - 9.99 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 22.00 (+214.29%) |
| Earnings Date | Dec 2, 2025 |
About NSRX
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for NSRX stock is "Strong Buy" and the 12-month stock price target is $22.0.
News
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
TEL AVIV, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasa...
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructu...
Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference
TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd.
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
TEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...
U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer
Eight issuers listed in the US this past week, six of which were eligible for inclusion in our IPO stats, joined by two SPACs. There are no IPOs currently scheduled for the week ahead, though some sma...
Nasus Pharma Announces Closing of Initial Public Offering
TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...
Nasus Pharma IPO Shows Promise But Risks Remain
Nasus Pharma is developing a needle-free intranasal epinephrine spray for severe allergies, showing promising but early trial results in a small population. The company is thinly capitalized, faces a ...
Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO
Nasus Pharma, a Phase 2 biotech developing an intranasal powder for severe allergies and anaphylaxis, filed on Wednesday with the SEC to raise up to $11 million in an initial public offering.
Nasus Pharma IPO Registration Document (F-1)
Nasus Pharma has filed to go public with an IPO on the NYSE American.